- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Coronary Artery Disease (CAD) and Peripheral Artery Disease (PAD)
- Meeting Date: July 2020
- Public Summary Document (PSD) July 2020 PBAC Meeting - (PDF 997KB)
- Public Summary Document (PSD) July 2020 PBAC Meeting - (Word 65KB)
Rivaroxaban – July 2020
Rivaroxaban: Tablet 2.5 mg; Xarelto®
Last updated
30 October 2020